News & Updates

Show Multimedia Only

Open surgery a better option than minimally invasive hysterectomy in early cervical cancer?

05 May 2022 by

Undergoing a minimally invasive radical hysterectomy leads to worse survival outcomes compared with open surgery in patients with early cervical cancer, according to final results of the LACC trial presented at SGO 2022.

05 May 2022

New HF guideline: Quad therapy, HFmrEF, and more

04 May 2022 by

Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.

04 May 2022

Sticking to a Mediterranean diet protects against pre-eclampsia

01 May 2022

Pregnant women with higher adherence to a Mediterranean‐style diet are at lower risk of pre-eclampsia, with the benefit observed among Black and White women, a study has found.

01 May 2022

Secondary OPINION analysis boosts safety profile of maintenance olaparib for ovarian cancer

29 Apr 2022 by

In women with platinum-sensitive relapsed ovarian cancer without a deleterious or suspected deleterious germline BRCA1/BRCA2 mutation (non-gBRCAm), maintenance olaparib was well tolerated, according to the secondary safety results from the phase IIIb OPINION study presented at SGO 2022.

29 Apr 2022

Should intraperitoneal chemo be reconsidered for ovarian cancer?

28 Apr 2022 by

Progression-free survival (PFS) is significantly longer with intraperitoneal (IP) over intravenous (IV) carboplatin, when combined with dose-dense paclitaxel, in patients with ovarian, fallopian tube, or primary peritoneal cancer, regardless of residual tumour size after initial surgery, according to the phase III iPocc* trial presented at SGO 2022.

28 Apr 2022

Infertility ups risk of heart failure in women

25 Apr 2022

A history of infertility among women appears to contribute to an increased risk of incident heart failure (HF), reveals a recent study.

25 Apr 2022

CHAP backs BP control during pregnancy, even for mild hypertension

23 Apr 2022 by

Actively treating even mild hypertension to a target blood pressure (BP) of <140/90 mm Hg in pregnant women significantly lowers the risk of adverse pregnancy outcomes without apparent harm to the foetus compared with a strategy of reserving treatment to only when hypertension becomes severe (≥160/105 mm Hg), according to the CHAP* study presented at ACC 2022.

23 Apr 2022

Tislelizumab a potential treatment alternative for gynaecologic MSI-H/dMMR tumours

20 Apr 2022 by

The humanized IgG4 monoclonal antibody tislelizumab was clinically active in women with gynaecologic microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) solid tumours, and was generally well-tolerated with no new safety signals, according to a subgroup analysis of the phase II RATIONALE 209 study presented at SGO 2022.

20 Apr 2022